<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483833</url>
  </required_header>
  <id_info>
    <org_study_id>VEN309-SMPEC-001</org_study_id>
    <nct_id>NCT01483833</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Iferanserin to Treat Hemorrhoids</brief_title>
  <official_title>Protocol for the Study of the Effects of S-MPEC (Iferanserin) in Patients With Hemorrhoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ventrus Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ventrus Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of topical 0.5% S-MPEC cream vs. placebo cream (applied
      twice daily for 14 days) in the treatment of Grade I - III hemorrhoids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of hemorrhoid bleeding</measure>
    <time_frame>Day 7 and 14</time_frame>
    <description>Change from pre-treatment in patient assessment of hemorrhoid bleeding (10-point scale: 1=Not at all, 10=Extremely) at the end of one- and two-weeks of treatment are the primary efficacy endpoints for the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of bleeding, hemorrhoid size, other hemorrhoid symptoms, and physician evaluation of hemorrhoids.</measure>
    <time_frame>14 days</time_frame>
    <description>Change from pre-treatment in patient assessment of bleeding on other treatment days, change from pre-treatment in hemorrhoid size, change from pre-treatment in patient assessment of other hemorrhoid symptoms/conditions on all treatment days, and physician evaluation of hemorrhoids at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Iferanserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iferanserin administration intra-anally twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration intra-anally twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iferanserin</intervention_name>
    <description>Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days</description>
    <arm_group_label>Iferanserin</arm_group_label>
    <other_name>VEN309</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ointment applied intra-anally twice daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Diagnosis of grade I - III hemorrhoids with bleeding episodes of at least every other
             day during the last two weeks before enrollment in the study.

          -  Patients signing the Informed Consent form.

        Exclusion Criteria:

          -  Patients with protruding or irreducible hemorrhoids (grade IV).

          -  Patients with anal fistulas, periproctitis or hemorrhagic diathesis

          -  Patients with current history of Type I or Type II diabetes mellitus.

          -  Patients with severe hepatic, renal or cardiovascular disorders.

          -  Patients with any type of infectious disease.

          -  Patients who have been involved with another experimental drug trial within the past
             30 days.

          -  Patients presently diagnosed with cancer.

          -  Patients who have known alcohol and drug abuse.

          -  Patients who require the use of suppositories.

          -  Patients with blood or urine laboratory values outside the normal limits or those with
             values considered abnormal in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prof. Alexander Herold, MD</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

